Zealand Pharma, Generate Biomedicines Strike $1.2B Obesity Drug Deal
GENB is trading near its 52-week low of $11 (13% above the low).
Summary
Generate Biomedicines and Zealand Pharma have entered a collaboration worth up to $1.2 billion to develop obesity treatments using AI. The deal includes $30 million upfront and $35 million in early milestone payments. This is a significant partnership for Generate, which has a market cap of about $1.57 billion, and validates its AI-driven drug discovery platform in a high-value therapeutic area. The agreement follows positive Phase 1 data for GB-0895 in asthma and COPD announced in August, and the launch of a CAR T trial with Roswell Park in October. The upfront and milestone payments provide near-term cash, while the total deal value signals substantial long-term potential. No specific upcoming event was disclosed.
At the time of this announcement, GENB was trading at $12.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $11.00 to $22.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.